Kingsview Wealth Management
GSK icon

Kingsview Wealth Management’s GSK GSK Stock Holding History

Kingsview Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$863K Buy
17,919
+2,468
+16% +$126K 0.01% 791
2026
Q2 		$810K Buy
15,451
+2,892
+23% +$153K 0.01% 809
2026
Q1 		$693K Sell
12,559
-881
-7% -$47.7K 0.01% 790
2025
Q4 		$659K Sell
13,440
-2,011
-13% -$93.8K 0.01% 758
2025
Q3 		$667K Buy
15,451
+311
+2% +$12.1K 0.01% 717
2025
Q2 		$581K Sell
15,140
-87
-0.6% -$3.32K 0.01% 722
2025
Q1 		$590K Buy
15,227
+271
+2% +$9.9K 0.01% 678
2024
Q4 		$506K Sell
14,956
-2,024
-12% -$72.9K 0.01% 734
2024
Q3 		$694K Sell
16,980
-227
-1% -$9.29K 0.01% 620
2024
Q2 		$662K Sell
17,207
-69
-0.4% -$2.9K 0.02% 607
2024
Q1 		$741K Buy
17,276
+563
+3% +$23.2K 0.02% 576
2023
Q4 		$619K Sell
16,713
-1,759
-10% -$63.1K 0.02% 591
2023
Q3 		$670K Buy
18,472
+1,355
+8% +$48.1K 0.02% 546
2023
Q2 		$610K Sell
17,117
-570
-3% -$20.4K 0.02% 541
2023
Q1 		$629K Sell
17,687
-29
-0.2% -$1.02K 0.03% 515
2022
Q4 		$623K Sell
17,716
-210
-1% -$7K 0.03% 455
2022
Q3 		$528K Buy
17,926
+3,892
+28% +$148K 0.03% 489
2022
Q2 		$764K Buy
14,034
+1,766
+14% +$97.5K 0.04% 431
2022
Q1 		$668K Sell
12,268
-754
-6% -$41K 0.03% 512
2021
Q4 		$718K Buy
13,022
+1,475
+13% +$76.7K 0.03% 489
2021
Q3 		$552K Buy
11,547
+219
+2% +$11K 0.03% 518
2021
Q2 		$569K Sell
11,328
-422
-4% -$20.3K 0.03% 528
2021
Q1 		$526K Buy
11,750
+1,763
+18% +$80K 0.03% 495
2020
Q4 		$459K Sell
9,987
-987
-9% -$45.3K 0.03% 462
2020
Q3 		$516K Sell
10,974
-364
-3% -$18.2K 0.05% 356
2020
Q2 		$578K Sell
11,338
-1,156
-9% -$59.3K 0.06% 300
2020
Q1 		$592K Buy
12,494
+3,240
+35% +$173K 0.08% 244
2019
Q4 		$544K Buy
9,254
+2,376
+35% +$132K 0.07% 268
2019
Q3 		$367K Buy
6,878
+2,256
+49% +$116K 0.06% 304
2019
Q2 		$231K Buy
4,622
+301
+7% +$15.1K 0.04% 368
2019
Q1 		$226K Buy
+4,321
New +$216K 0.03% 405

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
JTC Employer Solutions Trustee
JTC Employer Solutions Trustee St Helier, Jersey $1.16B AUM 24.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Mondrian Investment Partners
Mondrian Investment Partners London, United Kingdom $5.39B AUM 14.53% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $46.6B AUM 32.12% 1-Year Est. Return

Kingsview Wealth Management's GSK Position: Q3 2026 in Review

Kingsview Wealth Management increased its GSK (GSK) stake by 16% in Q3 2026, buying an estimated $126K and bringing the position to 17,919 shares worth $863K. The position accounts for 0.01% of the portfolio, ranked #791.

Kingsview Wealth Management first reported a position in GSK in Q1 2019 and has held it in 31 quarters since. 854 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

  • Kingsview Wealth Management held 17,919 shares of GSK worth $863K as of Q3 2026.
  • Kingsview Wealth Management bought 2,468 GSK shares in Q3 2026, an estimated $126K.
  • GSK made up 0.01% of Kingsview Wealth Management's portfolio in Q3 2026, its #791 holding.
  • Kingsview Wealth Management first reported a position in GSK in Q1 2019 and has held it in 31 quarters since.
  • 854 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Kingsview Wealth Management's 13F filing for Q3 2026, filed 13 Nov 2026.